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Summary
Objective: Time-lag from study completion to publication
is a potential source of publication bias in randomised con-
trolled trials. This study sought to update the evidence base
by identifying the effect of the statistical significance of
research findings on time to publication of trial results.
Design: Literature searches were carried out in four gen-
eral medical journals from June 2013 to June 2014 inclusive
(BMJ, JAMA, the Lancet and the New England Journal of
Medicine).
Setting: Methodological review of four general medical
journals.
Participants: Original research articles presenting the pri-
mary analyses from phase 2, 3 and 4 parallel-group rando-
mised controlled trials were included.
Main outcome measures: Time from trial completion to
publication.
Results: The median time from trial completion to publi-
cation was 431 days (n¼ 208, interquartile range 278–618).
A multivariable adjusted Cox model found no statistically
significant difference in time to publication for trials report-
ing positive or negative results (hazard ratio: 0.86, 95% CI
0.64 to 1.16, p¼ 0.32).
Conclusion: In contrast to previous studies, this review did
not demonstrate the presence of time-lag bias in time to
publication. This may be a result of these articles being
published in four high-impact general medical journals
that may be more inclined to publish rapidly, whatever
the findings. Further research is needed to explore the
presence of time-lag bias in lower quality studies and
lower impact journals.
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Introduction
Reporting bias (a widely researched issue concern-
ing the selective reporting of studies dependant on
the nature and signiﬁcance of results) has conse-
quences for the accurate dissemination of research
into practice. Publication bias is perhaps the most
widely researched form of reporting bias and occurs
when studies reporting ‘positive’ or statistically sig-
niﬁcant results are more likely to be published.1–3
Associated with this is time-lag bias, whereby the
nature and direction of study results inﬂuence time
to publication. Delayed or lack of publication may
result in ineﬀective or dangerous treatments being
implemented as the ﬁndings of positive studies
dominate the evidence base and bias treatment
decisions until some time has passed and the
papers reporting negative or null ﬁndings
appear.1,4 Moreover, Chalmers5 suggests that fail-
ure to publish the ﬁndings of research constitutes
scientiﬁc misconduct since it represents wasted
resources of funding agencies and of individual par-
ticipants’ time. Such concerns have recently been
raised following the delayed reporting of results
from the large-scale De-worming and Enhanced
Vitamin A trial of deworming and vitamin A.6
Publication of the ﬁndings from this trial, in
which one million children in India participated,
was delayed by eight years due to the authors’ con-
cerns that the results did not support current evi-
dence or policies on deworming practices.7 In
surgical trials, Chapman et al.8 have shown that
only 66% of completed trials were published, and
those that were took a median time of 4.9 years
from study completion to publication.
In a review of two earlier studies exploring time-
lag bias,9,10 an average two- to three-year delay in
publication of null or negative trial results has been
reported.4 This is supported by Decullier et al.,11
who found a statistically signiﬁcant diﬀerence in
the time to publication for positive and negative
study results (5.2 years compared to 6.5 years,
p< 0.001). Earlier studies are, however, limited by
topic area and location – Ioannidis10 explored only
AIDS trials, while Stern and Simes9 and Decullier
et al.11 concentrated on studies submitted to
research ethics committees in Australia and
France, respectively.
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Various studies have surveyed researchers to
explore reasons for non-publication or delayed pub-
lication, with ﬁndings suggesting that investigator-
related reasons tend to be the source of poorer
reporting of negative trial results, rather than rejec-
tion by journals.9,11–13 In survey studies exploring
publication bias, the rejection of manuscripts has
been cited as the reason for non-publication in only
5% of cases.11,13 Meanwhile, a recent review by van
Lent et al.14 supports the suggestion that time-lag
bias may be associated with delayed submission to
journals rather than delays associated with the
review process. In their review, the direction of results
had no eﬀect on the acceptance of manuscripts for
drug trials submitted to one general medical journal
and seven specialty journals.14
Our study updates and extends earlier research in
this ﬁeld by investigating the presence of time-lag bias
from the period between trial end and publication,
with no restrictions by topic area or trial location.
Methods
Search strategy and study selection
Four general medical journals (the BMJ, JAMA, the
Lancet and the New England Journal of Medicine)
were searched for randomised controlled trials pub-
lished between June 2013 and June 2014. An initial
database search of these journals yielded 685
potential articles reporting trial results (Figure 1),
which were then screened for initial inclusion by
one author. Original research articles presenting the
primary analyses from phase 2, 3 and 4 parallel-
group randomised controlled trials were included.
Studies reporting longer term follow-up or sub-
group analyses were excluded, as were cluster, factor-
ial, crossover, non-inferiority and equivalence trials.
Multiple co-authors checked article full-texts to
ensure all obvious exclusions had been removed.
Disagreements were resolved through discussion;
arbitration with a third reviewer was not necessary.
Figure 1. PRISMA flow diagram indicating the number of studies identified, included and excluded, and the reasons for exclusion,
in the review. In total, 208 studies were included in the quantitative analysis.
Records idenﬁed through 
database searching  
(n = 685) 
BMJ = 186 
JAMA = 165 
Lancet = 173 
NEJM = 161 
Records aer duplicates removed  
(n = 675) 
Records screened  
(n = 303) 
Records excluded  
(n = 372) 
Full-text arcles assessed 
for eligibility  
(n = 297)
Full-text arcles excluded, with 
reasons  
(n = 89) 
• Not a randomised trial (n = 5) 
• Not a parallel group RCT (factorial 
n = 15; non-inferiority n = 28; 
cluster n = 29; crossover n = 1) 
• Does not report primary outcome 
of trial (n = 7) 
• Reporng mulple trials (n = 3) 
• Phase 1 trial (n = 1) 
Studies included in 
quantave analysis  
(n = 208) 
Full-text arcle could not 
be retrieved 
(n = 6)
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Data extraction
Data extraction of each article was undertaken by two
independent authors using a standardised data extrac-
tion form. In order to calculate a time to publication,
the date of publication (online and/or in print) was
extracted. Where reported, the dates of completing
recruitment, completing follow-up and a trial end
date were extracted from the text. Additionally, a
date of trial completion was sought from online regis-
tries (ISRCTN Registry, ClinicalTrials.gov, or similar)
where possible.
In order to classify the trial ﬁndings as positive or
negative, the results of the analysis of the primary eﬃ-
cacy endpoint from each paper were extracted. The
following criteria were then applied: results were clas-
siﬁed as positive if they reported a statistically signiﬁ-
cant result (p< 0.05 or 95% conﬁdence interval (CI)
for the diﬀerence excluding 0, or 95% CI for a ratio
excluding 1) and negative otherwise. If multiple
p-values were reported relating to several speciﬁed
co-primary outcomes and/or time points, then the
results were classiﬁed as positive if the majority of
the p-values were signiﬁcant, and negative if non-sig-
niﬁcant. If there were the same number of signiﬁcant
and non-signiﬁcant results, or a primary outcome was
not speciﬁed, then the p-value relating to the outcome
used in the sample size was used where possible.
Study characteristics including journal, sample size
and trial location were also extracted from the texts.
Statistical analysis
A variable for time from trial completion to publica-
tion was derived. The hierarchical procedure for
deriving a trial end date was as follows:
. Explicit trial end date stated in the paper (e.g. ‘We
did this international, randomised, double-blind,
placebo-controlled, phase 3 trial between 6
October 2009 and 26 January 2012’).15
. Completion of primary data collection/follow-up
(e.g. ‘The recruitment of participants started in
December 2011, and the follow-up period ended
in September 2012’).16
. Approximate date of completion of follow-up
calculated by adding the maximum length of
follow-up to the recruitment end date.
. Date of completion given in online registry such as
ISRCTN.
If a date was given as a month and year only, it
was recorded as the 15th of that month for analysis
purposes.
Due to variation in the reporting of electronic
publication dates across papers and journals, for
consistency, the date of paper publication was used
to calculate time from study completion to publica-
tion. Time-to-event analyses were performed. Time to
publication was compared between the groups of
positive and negative trials using a log-rank test,
and Kaplan–Meier curves are presented. Since all
trials included in this analysis were published, there
was no censoring. Median time to publication is pre-
sented with its 95% CI. An adjusted analysis was
conducted using a Cox proportional hazards model
including actual sample size, journal and whether the
trial was conducted in one or multiple countries. The
proportional hazards assumption of the Cox model
was checked using log–log plots and tests of the
Schoenfeld residuals.
Statistical analysis was undertaken in Stata v13.17
All tests are two-sided at the 5% signiﬁcant level.
Results
In total, 298 full text articles were retrieved, of which
208 (70%) were considered eligible for inclusion in
this review (Figure 1); 22 (11%) from the BMJ,
67 (32%) from JAMA, 48 (23%) from the Lancet
and 71 (34%) from the New England Journal of
Medicine (Table 1). The trials were undertaken
Table 1. Characteristics of included studies.
Characteristic All (n¼ 208)
Year of publication, n (%)
2013 114 (55)
2014 94 (45)
Journal, n (%)
BMJ 22 (11)
JAMA 67 (32)
The Lancet 48 (23)
New England Journal of Medicine 71 (34)
Country, n (%)
Single 134 (64)
Multiple 74 (36)
Participants randomised
Mean (SD) 1673.8 (6510.7)
Median (min, max) 444 (13, 89835)
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globally and 74 (36%) were conducted across multiple
countries. The number of participants recruited into the
trials was highly variable with a range of 13 to 89,835
(in a randomised screening trial for breast cancer).18
The median number of participants recruited was 444.
Trial completion dates were recorded in online
registries for 179 trials (86%). The diﬀerences
between the trial end date derived from the paper
and the date given in the registry ranged from
3197 to 1706 days (approximately 9 to 5 years).
Negative diﬀerences indicate that the online registry
completion date is after the end date derived from
the paper suggesting, for instance, that the trial ﬁn-
ished early, was stopped early, or that longer term
follow-up is being conducted after the primary data
collection. Positive diﬀerences indicate that the trial
was completed later than originally planned. Only
100 (56%) trials ﬁnished within six months (before
or after) of their completion date as recorded in
their trial registration entry.
On average, trials took just over one year from
completion to publication (median 431 days, inter-
quartile range 278–618 days). There were two trials
with outlying times to publication beyond four years
of their derived completion date: the ﬁrst was a ran-
domised controlled trial of the varicella vaccine which
took nearly ﬁve years to be published (29 June 2009
to 12 April 2014)19 and the second was the aforemen-
tioned breast cancer screening trial, which took over
eight years to be published (31 December 2005 to 11
February 2014).18 In these trials, a non-signiﬁcant
primary result was reported in one and the ﬁndings
could not be classiﬁed in the other as a comparison
between the treatment groups for the primary end-
point is not reported.18,19
In total, 99 (48%) trials were classiﬁed as ‘nega-
tive’ and 94 (45%) as ‘positive’ (Table 2); 15 (7%)
trials could not be classiﬁed for reasons including
that the primary comparison of treatment groups
was not reported or no primary endpoint could be
identiﬁed.
Association between time to publication
and trial findings
Median time to publication was 412 days (approxi-
mately 13 months) (95% CI 328 to 459 days) among
negative trials and 433 days (approximately 14
months) (95% CI 378 to 485 days) among positive
trials. No statistically signiﬁcant diﬀerence was
observed by the log-rank test (p¼ 0.48). The
Kaplan–Meier curves for the proportion of trials
Table 2. Characteristics of analysed studies by classification as ‘positive’ or ‘negative’.
Characteristic
‘Positive’ trials
(n¼ 94)
‘Negative’
trials (n¼ 99)
Overall
(n¼ 193)
Year of publication, n (%)
2013 53 (56) 55 (56) 108 (56)
2014 41 (44) 44 (44) 85 (44)
Journal, n (%)
BMJ 4 (4) 18 (18) 22 (11)
JAMA 28 (30) 35 (35) 63 (33)
The Lancet 28 (30) 17 (17) 45 (23)
New England Journal of Medicine 34 (36) 29 (29) 63 (33)
Country, n (%)
Single 54 (57) 71 (72) 125 (65)
Multiple 40 (43) 28 (28) 68 (35)
Participants randomised
Mean (SD) 1034.9 (2079.8) 2347.2 (9170.2) 1708.0 (6741.6)
Median (min, max) 359 (13, 12000) 571 (31, 89835) 446 (13, 89835)
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published by positive and negative trials are shown in
Figure 2. In the Cox proportional hazards model, the
hazard ratio was 0.86 (95% CI 0.64 to 1.16), which
indicates that the rate of publishing following the end
of a trial is greater among negative trials, although
this result is not statistically signiﬁcant (p¼ 0.32). We
found no evidence that trials conducted in a single
country were published more quickly than inter-
national trials (HR 0.98, 95% 0.71 to 1.37,
p¼ 0.93), nor that sample size predicted time to pub-
lication (HR 1.00, 0.99 to 1.00, p¼ 0.08). The median
time to publication was lowest among trials published
in the New England Journal of Medicine (345 days),
followed by JAMA (421 days), the Lancet (498 days)
and the BMJ (511 days). Overall, journal was seen to
be a signiﬁcant predictor of time to publication
(chi-squared¼ 8.19, df¼ 3, p¼ 0.04). The main
result was robust; Cox models including journal as
a random (as opposed to ﬁxed) eﬀect, logging the
sample size covariate and excluding the eight-year
outlier were run and produced hazard ratios between
0.83 and 0.90 (p-values between 0.11 and 0.49).
In assessment of the validity of the proportional
hazards assumption, although log–log plots for the
qualitative covariates in the Cox model showed evi-
dence of non-parallel lines, covariate-speciﬁc and
global tests of the Schoenfeld residuals did not indi-
cate that the assumption was violated.
Discussion
This paper provides an updated review of the eﬀect of
trial ﬁndings on time to publication in randomised
controlled trials. Our ﬁndings show no evidence of
time-lag bias; no statistically signiﬁcant diﬀerence was
found in the time from study completion to publication
for trials reporting signiﬁcant and non-signiﬁcant
primary results. The large scale and systematic
nature of this review, with no restrictions by topic
or location, extends the evidence base, which has pre-
viously focussed on exploring time-lag bias in speciﬁc
settings or disease areas.9–11 Our ﬁndings contrast
these earlier studies, which could indicate that initia-
tives such as the AllTrials campaign, started in
January 2013, which advocates all clinical trials be
registered and reported, are achieving relative suc-
cess.20 However, it is also possible that the selection
of high impact factor journals for this review may
have inﬂuenced the likelihood of detecting time-lag
bias as these journals publish greater quality studies
that may be published more quickly, regardless of the
results. Further research is needed to explore the
presence of time-lag bias in a wider array of journals.
The reasons for time-lag in lower impact journals
may be more varied and could include rejections
from other journals, lower quality submissions
requiring more extensive revisions and less eﬃcient
Figure 2. Kaplan–Meier curves indicating time to publication for both positive and negative trials. The rate of publishing fol-
lowing the end of a trial is greater among negative trials (HR 0.86), although this result is not statistically significant (p¼ 0.32).
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peer-review processes (less staﬀ or diﬃculty recruiting
reviewers).
Although not shown to be related to signiﬁcance
of trial ﬁndings, considerable time delay appears to
be present in the reporting of trial results in the
included studies. On average trials took just over
one year from completion to publication and these
data were positively skewed, with some trials taking
several years to publish. For thoroughness, we con-
tacted the authors of two outliers to ascertain reasons
for these long delays (eight years – Miller et al.18 and
ﬁve years – Prymula et al.19). Prymula et al. claimed a
number of reasons for the delay, most notably inves-
tigation into the GCP issues in Poland outlined in the
manuscript; while Miller et al. cited extensive delays
in obtaining cancer registry data and initial rejection
of their research article as the cause of the publication
delay (personal communication). Of course, a truer
reﬂection of the intention to publish swiftly would
involve investigating the time between trial comple-
tion and the date of initial submission, rather
than publication. Previous reviews focusing on the
inﬂuence of the peer-review process on time-to-
publication suggests that it can add to the delay
if not completed in a timely fashion14 and high-
impact journals are likely to request extensive revi-
sions which can be time-consuming to address.
Unfortunately, the date of submission is not com-
monly easily accessible.
While the delays in publication found in this
review are concerning as they may hinder alterations
in clinical practice, these ﬁndings represent just a
snapshot of the potential problem. Trials that are
never published is a separate and potentially more
detrimental issue that could not be explored through
the methods of this review; however, recent research
suggests that in some ﬁelds of medicine up to 34% of
completed trials remain unpublished.8 Funding
bodies have a vested interest in encouraging research-
ers to publish in order for them to see a maximum
return on their investment. For many, if not all, fund-
ing bodies, it is required from an early stage to
consider and declare how the ﬁndings from the
research will be disseminated, and publication is
strongly recommended. The National Institute for
Health Research (NIHR) Health Technology
Assessment (HTA) Programme for instance aims to
publish a report, or monograph, for each project it
commissions. Research teams are contractually obli-
gated to write and submit this report upon comple-
tion of their study; therefore, the results from these
projects are published irrespective of the ﬁndings. In
addition, authors are encouraged to disseminate their
ﬁndings through a publication in a peer-reviewed
journal, and we suspect that having written a lengthy
and comprehensive report, authors would be more
likely to submit a journal article which is much
shorter and could be relatively easily compiled with
detail adapted from the monograph.
Our analysis of time to publication by journal sug-
gests that journal Impact Factors may have inﬂu-
enced time to publication, with those articles
published in higher impact journals tending to be
published earlier. According to recent Journal
Citation Reports at the time of writing this article,
New England Journal of Medicine has an impact
factor of 54.4, the Lancet of 39.2, JAMA of 30.4
and the BMJ of 16.4, which resembles the order of
median time to publication (New England Journal of
Medicine 345 days, JAMA 421 days, the Lancet 498
days and the BMJ 511 days). This lag time may be
introduced if articles are rejected by higher impact
journals and then require resubmission elsewhere;
therefore, time-lag bias is likely to be more problem-
atic in journals with a lower impact factor.
We encountered diﬃculty when determining trial
end dates for this study due to wide variations in trial
end dates reported through online registries and those
derived from publications. This ﬁnding was surpris-
ing given that Consolidated Standards of Reporting
Trials (CONSORT) recommends deﬁning the periods
of recruitment and follow-up and all four medical
journals searched are CONSORT endorsing journals
that require completion of a CONSORT checklist
during submission. In some instances, online regis-
tries did not report completion dates, and in others,
the dates reported had not been updated as the trial
progressed and were often wildly inconsistent with
those reported in the journal publications. This sup-
ports ﬁndings from an earlier paper by Zarin et al.21
which reviewed the completeness of data entered into
the ClinicalTrials.gov registry. To overcome this
problem of poor reporting in online registries, we
attempted to extract a trial completion date from
trial publications, but again large inconsistencies in
reporting made this diﬃcult. Some texts clearly
report the dates of commencing recruitment, the
date of completing recruitment and the date of ﬁnal
primary follow-up/data collection, whilst others give
very little indication of such timings. Occasionally,
texts report a date the study was completed on, or
give a range of dates in which the study was con-
ducted; however, it is often unclear what exact deﬁn-
ition of completion the authors have used. Options
may include date of last data collection, date the data
were handed over for analysis meaning all data had
been collected and data queries resolved, or perhaps
the date the trial funders required their report to be
submitted. This study therefore highlights the import-
ance of transparent reporting of trial start and end
6 Journal of the Royal Society of Medicine Open 7(10)
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dates, and the need for trialists to update online regis-
tries throughout the trial to improve the accuracy of
the information held. We used a standardised hier-
archy to determine a trial end date in this study,
which we recommend be adopted by researchers
extracting this information from trial publications
in the future.
Conclusions
In contrast to previous studies, we did not ﬁnd a sig-
niﬁcant diﬀerence in publication lag time between
‘positive’ and ‘negative’ trials. While this may reﬂect
improved research practices as a result of recent ini-
tiatives such as the AllTrials20 campaign, it may be
that these high impact journals only publish the high-
est quality studies which are relatively rapidly pub-
lished, whatever their ﬁndings. Time-lag publication
bias might be worse among studies published in jour-
nals with a lower impact factor. Further research
could explore this through sensitivity analysis using
quality of studies in meta-analyses.
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